CTLA4 and atopic eczema: The patient showed marked improvement in eczema severity scores, including a sixfold reduction in the Eczema Area and Severity Index and a threefold reduction in the Dermatology Life Quality Index over 6 months, highlighting Dupilumab’s potential role in cytotoxic T lymphocyte-associated antigen 4-deficient patients experiencing atopic dermatitis.